We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Stock Moves -0.81%: What You Should Know
Read MoreHide Full Article
Teladoc (TDOC - Free Report) closed the most recent trading day at $26.81, moving -0.81% from the previous trading session. This change was narrower than the S&P 500's 1.03% loss on the day. At the same time, the Dow lost 1.15%, and the tech-heavy Nasdaq gained 0.37%.
Coming into today, shares of the telehealth services provider had lost 11.67% in the past month. In that same time, the Medical sector lost 0.28%, while the S&P 500 lost 3.51%.
Teladoc will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$0.59, down 11.32% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $608.82 million, up 16.71% from the year-ago period.
TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$61.39 per share and revenue of $2.4 billion. These results would represent year-over-year changes of -4515.79% and +18.09%, respectively.
Any recent changes to analyst estimates for Teladoc should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 6.33% higher within the past month. Teladoc is currently a Zacks Rank #3 (Hold).
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Stock Moves -0.81%: What You Should Know
Teladoc (TDOC - Free Report) closed the most recent trading day at $26.81, moving -0.81% from the previous trading session. This change was narrower than the S&P 500's 1.03% loss on the day. At the same time, the Dow lost 1.15%, and the tech-heavy Nasdaq gained 0.37%.
Coming into today, shares of the telehealth services provider had lost 11.67% in the past month. In that same time, the Medical sector lost 0.28%, while the S&P 500 lost 3.51%.
Teladoc will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$0.59, down 11.32% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $608.82 million, up 16.71% from the year-ago period.
TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$61.39 per share and revenue of $2.4 billion. These results would represent year-over-year changes of -4515.79% and +18.09%, respectively.
Any recent changes to analyst estimates for Teladoc should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 6.33% higher within the past month. Teladoc is currently a Zacks Rank #3 (Hold).
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.